NFAT3 and TGF-β/SMAD3 regulate the expression of miR-140 in osteoarthritis by unknown
Tardif et al. Arthritis Research & Therapy 2013, 15:R197
http://arthritis-research.com/content/15/6/R197RESEARCH ARTICLE Open AccessNFAT3 and TGF-β/SMAD3 regulate the expression
of miR-140 in osteoarthritis
Ginette Tardif, Jean-Pierre Pelletier, Hassan Fahmi, David Hum, Yue Zhang, Mohit Kapoor
and Johanne Martel-Pelletier*Abstract
Introduction: MicroRNAs (miRNAs) down-regulate their target genes. The intronic miR-140, present in the WW
domain containing E3 ubiquitin protein ligase 2 (WWP2) gene, decreases the expression of genes that play
detrimental roles in osteoarthritis (OA). As the expression level of miR-140 is significantly decreased in human OA
chondrocytes, we investigated its regulation in those cells.
Methods: Gene expression in human chondrocytes was determined by quantitative polymerase chain reaction
(qPCR) and gene silencing was done in OA chondrocytes by transient transfection with specific small interfering
RNAs (siRNAs). Binding sites of the miR-140 regulatory sequence (rsmiR-140) were identified by mutagenesis and
chromatin immunoprecipitation (ChIP) in OA chondrocytes. The effects of translocation on OA chondrocytes were
determined by immunocytochemistry and qPCR.
Results: In contrast to miR-140, the expression of WWP2 was similar in both normal and OA cells, suggesting that
miR-140 has an additional level of regulation. rsmiR-140 showed activity and predicted binding sites for nuclear
matrix transcription factor 4 (NMP4), myc-associated zinc (MAZ), nuclear factor of activated T-cells (NFAT), and
mothers against decapentaplegic homolog 3 (SMAD3). Silencing NFAT3 (P ≤0.01) and SMAD3 (P ≤0.05) differentially
regulated miR-140 independently of WWP2. Silencing NFAT5 decreased both miR-140 and WWP2 (P ≤0.003 and
P ≤0.05, respectively). NFAT3 activation increased and transforming growth factor-β (TGF-β) decreased rsmiR-140
activity. Mutagenesis of rsmiR-140 and ChIP assays identified binding sites at which NFAT3 (activator) and SMAD3
(repressor) directly regulated miR-140. TGF-β interfered with NFAT3 translocation, and subsequently with miR-140
expression.
Conclusions: This is the first study to provide evidence of a regulatory mechanism of miR-140 independent of
WWP2, and new and differential roles for NFAT3 and SMAD3 in the OA process in the regulation of miR-140
transcription. Such knowledge could advance therapeutic strategies targeting OA.Introduction
MicroRNAs (miRNAs) add another level of regulation to
gene expression by down-regulating their target genes.
Some miRNAs including miR-146 and miR-155 have
been linked to arthritis pathologies, such as rheumatoid
arthritis [1-3], but miR-140, originally found in cartilage
[4], has been linked more specifically to osteoarthritis
(OA) [5,6]. miR-140 decreases the expression of genes
known to play detrimental roles in OA cartilage. Among
them are histone deacetylase 4 [4], which was recently* Correspondence: jm@martelpelletier.ca
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre
(CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal,
Quebec H2L 4M1, Canada
© 2013 Tardif et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orshown to interact with Runx2, a repressor of matrix
metalloproteinase-13 (MMP-13) transcription [7], A dis-
integrin and metalloproteinase with a thrombospondin
type 1 motif (ADAMTS-5) [8], whose deletion generated
OA-like changes [9,10], mothers against decapentaplegic
homolog 3 (SMAD3) [11], a mediator of transforming
growth factor-β (TGF-β) signaling reported to be associ-
ated with hip and knee OA in European populations
[12] and insulin-like growth factor-binding protein-5
(IGFBP5) [5] an important factor in IGF-1 storage in the
joint [13] whose increase is associated with reduced car-
tilage destruction [14]. Targeted deletion of miR-140 in
mice resulted in age-related OA-like changes [8]. Of im-
portance, miR-140 expression is significantly decreasedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased expression of its target genes and consequently
a role in cartilage degradation.
miR-140 is found in one intron of the WW domain
containing E3 ubiquitin protein ligase 2 (WWP2) gene
[15]. Analysis of the intronic sequence has revealed the
presence of two miR-140 s, miR-140-5p and miR-140-3p.
All of the previous studies done with arthritic cells and tis-
sues used miR-140-5p. Although both miR-140-5p and
-3p are transcribed from the same precursor transcript
pre-miR-140, they have different seed sequences and are,
therefore, predicted to target different genes. While miR-
140-5p was shown to target several genes involved in
OA, miR-140-3p has been reported to target dynamin 1,
which plays a role in the central nervous system [16] and
the nuclear factor kappa B (NF-κB) co-activator nuclear
receptor-interacting protein 1 [17].
Because of its role in inhibiting key factors involved in
OA pathophysiology and its down-regulation in OA
cartilage, understanding the transcriptional regulation
of miR-140 in this pathological condition is of great im-
portance and could open up new therapeutic avenues tar-
geting this disease.
Methods
Specimen selection
Human cartilage was obtained from femoral condyles and
tibial plateaus. Normal human cartilage was obtained from
individuals within 12 hours of death (n = 8, 60 ± 19 years
(mean ± SD)) and OA cartilage from patients undergoing
total knee arthroplasty (n = 48, 66 ± 9 years). Normal indi-
viduals had no history of joint disease and died of causes
unrelated to arthritic diseases. The cartilage was examined
macroscopically and microscopically to ensure that only
normal tissue was used. All OA patients had been evaluated
by a certified rheumatologist and diagnosed as having OA
according to the American College of Rheumatology (ACR)
criteria [18]. These specimens represented moderate to se-
vere OA. The Institutional Ethics Committee Board of the
University of Montreal Hospital Research Centre
(CRCHUM) approved the use of the human articular tis-
sues. Patients signed informed consent and post-mortem
tissue was obtained with the consent of a family member
or authorized individual.
Cell culture
Chondrocytes were seeded directly from the digested cartil-
age (primary chondrocytes) as described [5] and the
SW1353 chondrosarcoma cell line was purchased from
American Type Culture Collection, Manassas, VA, USA
(#HTB-94). Briefly, the cells were seeded at high density
(105/cm2) and cultured in (Dulbecco’s) modified Eagle’s
medium ((D)MEM; Wisent, St-Bruno, QC, Canada) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS;PAA Laboratories Inc, Etobicoke, ON, Canada) and an
antibiotic mixture (100 units/ml penicillin base and
100 μg/ml streptomycin base; Wisent) at 37°C in a hu-
midified atmosphere. Primary chondrocytes were used
when comparing expression levels in normal and OA
chondrocytes to avoid loss of the chondrocyte phenotype
and first-passage chondrocytes for all other experi-
ments involving cultured chondrocytes. In the experi-
ments, the culture medium was replaced with (D)
MEM containing 0.5% FCS 24 hours before the treat-
ment. The ionophore ionomycin (1 μM; Sigma, Oak-
ville, ON, Canada), NaCl (100 mM), and TGF-β
(10 ng/ml, Feldan Bio Inc., Montreal, QC, Canada)
were added for 18 hours and the specific inhibitor of
SMAD3 phosphorylation (SIS3, 8 μM; Calbiochem, La
Jolla, CA, USA) [19] for 24 hours.
Quantification of mRNA and miRNA
Total RNA was extracted and quantified as described [5]
except that 10 μg glycogen was added to the precipita-
tion step to enrich for miRNAs. mRNA levels were
quantified by real-time PCR with the SYBR Green PCR
Master Mix (Qiagen, Valencia, CA, USA). When quanti-
fying expression between normal and OA chondrocytes,
internal standards were added at known concentrations
in the PCR reactions and amplified by the same primers
as the specific target mRNAs as to give absolute num-
bers. The values of each sample were calculated as the
ratio of the number of molecules of the target gene/
number of molecules of the housekeeping gene. When
evaluating the effect of a treatment on a given cell cul-
ture, the expression level of each control was assigned
an arbitrary value of 1, and the treated cells were evalu-
ated as fold change over control and calculated as 2-Δ(ΔCt).
Basal expression values of the control specimens (as deter-
mined from the number of molecules of the target
gene/housekeeping gene) are shown in Additional file 1:
Figure S1. Primer efficiencies for the genes under study
were the same as those for the housekeeping gene glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). The se-
quences of the human specific primers used are listed in
Table 1. miRNAs were quantified with the TaqMan Micro-
RNA Reverse Transcription kit and TaqMan MicroRNA
Assays specific for each mature miRNA (Applied Biosys-
tems, Burlington, ON, Canada) as described [5]. Normal-
isation of the miRNA expression data was done using the
GAPDH gene. The expression level of each control was
assigned an arbitrary value of 1 and the treated cells were
evaluated as fold change over control.
Gene silencing
siRNA pools specific for NMP4, MAZ, NFAT1 (NFATc2),
NFAT2 (NFATc1), NFAT3 (NFATc4), NFAT4 (NFATc3),
NFAT5 (TonEBP) and SMAD3 were purchased from
Table 1 Sequences of the human gene-specific primers
used for qPCR
Gene Sequence
(GenBank accession number)
FAK 5’-AGAAGTATGAGCTTGCTCAC (S)
(NM_153831.2) 5’-TGATCGCCGTATTTCTAGAC (AS)
GAPDH 5’-CAGAACATCATCCCTGCCTCT (S)
(NM_002046.3) 5’-GCTTGACAAAGTGGTCGTTGAG (AS)
IGFBP5 5’-TGAAGCAGTGAAGAAGGAC (S)
(NM_000599) 5’-CTGCTTTCTCTTGTAGAATC (AS)
MAZ 5’-GATCACCTCAACAGTCACGTC (S)
(NM_002383.2) 5’-CTGTGCACCTTCATGTGGTC (AS)
NFAT1 (NFATc2) 5’-AGAATCCATCCTGCTGGTTC (S)
(NM_012340) 5’-TCCATGTAGCCATGGAGCTG (AS)
NFAT2 (NFATc1) 5’-TCATTGACTGTGCCGGAATC (S)
(NM_172390) 5’-AAGTTGTGGCCAGACAGGAC (AS)
NFAT3 (NFATc4) 5’-AGAACTGGACTCAGAGGATG (S)
(NM_004554) 5’-ATGGAGGTGATGCGGATG (AS)
NFAT4 (NFATc3) 5’-CCAGCCCGGGAGACTTCAATAGAT (S)
(NM_173165) 5’-GCCCAGGAGCTTCACAACAGGAT (AS)
NFAT5 (TonEBP) 5’-CTGAGCAGAGCTGCAGTATG (S)
(NM_138713) 5’-GTTGTCCGTGGTAAGCTGAG (AS)
NMP4 5’-CGTACTTCTGGCCTTCTATC (S)
(AB070238) 5’-CAGTCATCAGTCCTGTAGAC (AS)
SMAD3 5’-GTCTGCAAGATCCCACCAGG (S)
(NM_005902) 5’-CTTGTCAAGCCACTGCAAAG (AS)
SREBF2 5’-TGAGATCCATCTGACTGCTG (S)
(NM_004599) 5’-CCTCTGGGCACAGTATAGAC (AS)
WWP2 5’-CAAGGTGCATAATCGTCAAC (S)
(NC_000016) (variants 1, 3) 5’-GATGCGGTGCCTAGCAGTTC (AS)
WWP2 5’-TCCTCCTGTCTCATGAGGTG (S)
(NC_000016) (variants 1, 2) 5’-GCCTATAAAGCGAAAGTAGG (AS)
S sense, AS antisense.
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HiPerfect Transfection Reagent (Qiagen) at a concentration
of 100 nM. Total RNA was extracted after 48 hours and
mRNA levels measured by quantitative PCR and normalised
to the control gene. Cells transfected with non-targeting
(random) siRNAs served as controls. Silencing gene expres-
sion was carried out by transfecting OA chondrocytes for
48 hours with small interfering RNAs (siRNAs), resulting in
a silencing efficiency of more than 80% as described [20]
and as illustrated in Additional file 2: Figure S2.
Cloning of the 5’-flanking region of pre-miR-140
(rsmiR-140)
1.883 kb of the 5’-flanking region directly upstream of
pre-miR-140 (regulatory sequence miR-140 (rsmiR-140))was cloned into the luciferase reporter vector pGL3-
basic (Promega, Madison, WI, USA). The fragment was
amplified by PCR using genomic DNA from human chon-
drocytes and the primers 5’-TGAGCTAGCGGTGC
TTATGACCGCAGTTTTC (sense) and 5’-CAGAAG
CTTACCAAGCAGAGCCTGGAGAGGAG (antisense).
NheI and HindIII restriction sites (bold) were added to
the sense and antisense primers, respectively, to facilitate
the cloning into the NheI and HindIII sites of the pGL3-
basic vector. A smaller plasmid was constructed simi-
larly by using the sense oligonucleotide 5’-TGAGCTA
GCGTGCCCCGGAAGGCTGCCCTGTAC, resulting in a
cloned fragment of 1.153 kb. Both plasmids were sequenced
to confirm the integrity of the cloned DNA.
Wild-type and mutated oligonucleotides were chem-
ically synthesised and used in site-directed mutagenesis
assays with the QuickChange Site-Directed Mutagenesis
kit (Stratagene, La Jolla, CA, USA) as described [21].
Bases were mutated to change the consensus NFAT bind-
ing site GGAAA to GGTAC, and the SMAD3 consensus
binding sites from CAGA to TACC and from TTGG
TGTTGG to TTGCATATGG. Each plasmid was verified
by DNA sequencing.
Transfection and rsmiR-140 activity
The SW1353 cells were transfected with the TransFectin
transfection reagent (Bio-Rad, Mississauga, ON, Canada),
incubated for 48 hours in (D)MEM/10% FCS and lysed in
Reporter Lysis buffer (Promega). The transfected cells
were then incubated for an additional 18 hours with the
factor under study. Luciferase activity was measured with
the Lumat LB 9507 luminometer (EG&G Berthold, Bad
Wildbad, Germany). To monitor transfection efficiency, a
plasmid coding for a green fluorescent protein was used.
Total protein was quantified by the bicinchoninic acid
method (Pierce, Rockford, IL, USA). Plasmid activity was
calculated as relative luciferase units per μg of protein.
The pGL3-basic control was assigned an arbitrary value of
1 for each experiment and the activity evaluated as fold
change over control. Basal expression values of the control
specimens as determined by luciferase units/μg of protein
are shown in Additional file 1: Figure S1.
Western blotting
OA chondrocytes were treated with ionomycin (1 μM,
60 minutes), NaCl (100 mM, 60 minutes) or TGF-β
(10 ng/ml, 30 minutes). Nuclear proteins from the con-
trol and treated cells were extracted with the Nuclear
Extraction kit (Cayman Chemical Company, Ann Arbor,
MI, USA) and processed (5 μg) for Western blotting as
previously described [21]. The primary antibodies were a
rabbit anti-human SMAD3 (Cell Signaling Technology,
Danvers, MA, USA; dilution 1/2,000), a mouse anti-
human NFAT3 (Santa Cruz Biotechnology, Santa Cruz,
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(Novus Biologicals, Littleton, CO, USA; dilution 1/
5,000). The secondary antibodies were an anti-mouse or
anti-rabbit immunoglobulin G (IgG; Pierce, Rockford,
IL, USA; dilution 1/10,000). The nuclear protein nucleo-
lin (Active Motif, Carlsbad, CA, USA; dilution 1/5000)
was used as a housekeeping (control) protein.
Chromatin immunoprecipitation
OA chondrocytes were treated with TGF-β (10 ng/ml,
30 minutes) or ionomycin (1 μM, 60 minutes) and
processed with the EZ-Magna ChIP A/G Chromatin
Immunoprecipitation Assay kit (Millipore, Temecula,
CA, USA) as recommended by the manufacturer and
as described [22]. The antibodies used in the chroma-
tin immunoprecipitation (ChIP) reactions were an anti-
human SMAD3 (Cell Signaling Technology) and an anti-
human NFAT3 (Santa Cruz Biotechnology). Pre-immune
IgGs were used as negative control. The PCR primers
were 5’-GCATTGTCTTGCCTTCACCC (sense, located
52 bp upstream of the NFAT3 binding site) and 5’-TGGA-
GAGGAGGTCACCACGG (antisense, located 200 bp
downstream from the NFAT3 site). These primers were
also used for the SMAD3 ChIP assay, as the NFAT3 and
SMAD3 sites are separated by less than 40 bp. The primer
sequences of the MAP1A gene (microtubule-associated
protein 1A, used as an unrelated control gene) were 5’-
GACCTTATGCCAGGACAGGA (sense) and 5’-AGAC
AAGAGCTCCCTCCACA (antisense). The pre-immune
IgG ChIP results were used as negative control and the
data from the NFAT3 and SMAD3 experiments were nor-
malized to this control. The genomic DNA (1% of the
starting lysate input) was used as positive control. The
amplified PCR products were analysed on agarose gels
and quantitated by qPCR. The results were compared to
those of the pre-immune assays, and the effect of the
treatment measured as fold change over the control which
was assigned an arbitrary value of 1. Basal expression
values of the control specimens (as determined by PCR
control values per input control DNA) are shown in
Additional file 1: Figure S1.
Nuclear translocation
Nuclear translocation of SMAD3 and NFAT3 was assessed
in OA chondrocytes by immunocytochemistry and its ef-
fect by qPCR.
Immunocytochemistry
Cells were cultured on Permanox slides (Thermo Fisher
Scientific, Ottawa, ON, Canada). The effect of TGF-β on
NFAT3 translocation was monitored by treating the cells
with ionomycin (1 μM) for 90 minutes, with TGF-β
(10 ng/ml) added for the last 30 minutes of the incu-
bation. The effect of ionomycin/NFAT3 on SMAD3translocation was examined by treating the cells with
TGF-β (10 ng/ml) for 90 minutes and ionomycin
(1 μM) for the last 60 minutes. The cells were fixed
with 4% paraformaldehyde for 30 minutes at 4°C,
washed with PBS and treated with 10% NH4Cl. The
cells were then permeabilised with 0.3% Triton X-100
for 30 minutes at room temperature, blocked with 1%
BSA for one hour at room temperature, and probed
with the specific antibodies overnight at 4°C.
The primary antibodies were a rabbit anti-human
SMAD3 (1 μg/ml, Abcam, Cambridge, MA, USA) and
a mouse anti-human NFAT3 (5 μg/ml, Santa Cruz
Biotechnology). The slides were then incubated for
one hour at room temperature with the secondary
antibodies (10 μg/ml, biotinylated anti-mouse or anti-
rabbit IgG, Vector Laboratories, Burlingame, CA, USA
and Life Technologies, Burlington, ON, Canada, respect-
ively). Streptavidin-coupled ALEXA 488 (10 μg/ml, Life
Technologies) was added (one hour in the dark at
room temperature) and the nuclei were counterstained
with 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI,
Molecular Probes, Eugene, OR, USA). The slides were
mounted with Vectashield (Vector Laboratories). Images
were acquired using a Zeiss Axio microscope and its
processing software AxioVision with the monochro-
matic AxioCam MRm camera (Zeiss Canada, Toronto,
ON, Canada).
Control procedures were performed according to the
same experimental protocol by (i) omission of the pri-
mary antibody, and (ii) substitution of the primary anti-
body with a non-specific IgG from the same host as the
primary antibody (Santa Cruz Biotechnology). Control
slides showed only background staining. The total num-
ber of chondrocytes and the number of chondrocyte
nuclei staining positive for NFAT3 or SMAD3 were
counted in five random representative fields. Results
were calculated as the percentage of the total number
of chondrocytes staining positive.
Effect of nuclear translocation on miR-140 expression
OA chondrocytes were incubated with ionomycin (1 μM)
or TGF-β (10 ng/ml) for two to twenty hours; TGF-β was
added during the ionomycin treatment and ionomycin
added during the TGF-β treatment. Preliminary experi-
ments revealed a maximum effect at eight hours, with
TGF-β added to the last 6½ hours of the ionomycin treat-
ment and vice-versa. miR-140 expression was determined
by qPCR as above.
Statistical analysis
Values are expressed as mean ± standard error of the
mean (SEM). Statistical significance was assessed with
the Mann–Whitney test or a one-sample t-test where
appropriate; a P value ≤0.05 was considered significant.
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Differential expression levels of miR-140 and WWP2
We previously reported that miR-140-5p expression was
significantly reduced in human OA chondrocytes [5].
Here, we followed this by comparing its expression to
that of miR-140-3p, and their host gene, WWP2, in
normal and OA human chondrocytes. Data showed
(Figure 1A, B) that the expression levels of miR-140-5p
and -3p were both markedly and significantly reduced
in OA chondrocytes. Interestingly, WWP2 expression
(Figure 1C) was only slightly reduced (about 21%) in
OA and this did not reach statistical significance. Of
note, these results represent the global expression of
the mRNAs and miRNAs at a given point in time.
The WWP2 gene codes for three variants or isoforms.
Variant 1 (FL-isoform) is the longest variant with 25
exons; variant 2 (C-isoform) has its ATG in exon 14 of
variant 1 and the same TAA stop codon as variant 1;
variant 3 (N-isoform) has the same ATG as variant 1 but
with a stop codon in exon 10. Preliminary RT-PCR ex-
periments using primers specific for variants 2 and 3
[23] have shown that these variants were not as stronglyFigure 1 Expression of miRNAs and their host genes. Expression (numb
housekeeping gene) of the intronic miRNAs A) miR-140-5p, B) miR-140-3p,
SREBF2, of F) miR-151 and G) its host gene PTK2/FAK in human normal (n
assessed by the Mann–Whitney test comparing OA to normal chondrocyteexpressed as variant 1 in human chondrocytes. Variant 3
was expressed in both normal and OA chondrocytes and
the expression pattern was similar to that observed with
variant 1 (data not shown); variant 2 was either not
expressed or very weakly expressed in chondrocytes (data
not shown). We have routinely used primers located in
exons 4 and 5 (variants 1 and 3, Figure 1C). Experiments
performed with primers located in exons 14 and 16
(variants 1 and 2) (Additional file 3: Figure S3 A) showed
similar data to those with the variants 1 and 3 and yielded
no significant differences between the two sets of primers.
Subsequent experiments were done using primers located
in exons 4 and 5.
To determine whether the differential expression level
between WWP2 and miR-140 was due to a different
miRNA processing in OA cells, we determined the levels
of two unrelated intronic miRNAs: miR-33a (Figure 1D)
present in one intron of the sterol regulatory element
binding factor-2 (SREBF2) gene and miR-151 (Figure 1F),
present in one intron of the protein tyrosine kinase or
focal adhesion kinase (PTK2/FAK) gene. The expression
levels of miR-33a (Figure 1D) and its host gene SREBF2er of molecules of the target gene/number of molecules of the
and C) their host gene WWP2, of D) miR-33a and E) its host gene
= 6) and osteoarthritic (OA) (n = 6) chondrocytes. P values were
s. miRNAs, microRNAs.
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however, the expression level of miR-151 (Figure 1F) was
significantly decreased compared to that of its host gene
PTK2/FAK (Figure 1G). These findings indicate that the
reduced expression of miR-140 in OA chondrocytes is not
due to a general processing and likely results from an
additional level of regulation specifically directed at
this miRNA.
Identification of an intronic regulatory sequence
upstream of pre-miR-140
Intronic miRNAs can be regulated independently of their
host gene by sequences located directly upstream of their
precursor sequence. To determine if such was the case for
miR-140 and WWP2, we cloned 1.883 kb and 1.153 kb
(Figure 2A) of the sequence located directly upstream of
the pre-miR-140 [GenBank:NC_000016]. Both plasmids
promoted similar transcriptional activity (Figure 2B), indi-
cating the presence of regulatory elements in the sequence
upstream of pre-miR-140. Further experiments wereFigure 2 miR-140 sequence and activity of rsmiR-140. A) Sequence of
the WWP2 gene. The letters in bold represent the seed regions of the mat
pre-miR-140 (shown between the diagonal lines) that was cloned into the
(rsmiR-140) with the location of potential transcription factor binding sites.
in SW1353 cells (n = 4). Plasmid activity was calculated as relative luciferase
arbitrary value of 1 for each experiment and the rsmiR-140 activity evaluate
one-sample t-test, comparing rsmiR-140 to the pGL3-basic vector.conducted with the 1.153 kb cloned DNA, designated in
the text rsmiR-140.
Identification of NFAT3 and SMAD3 as regulators of
miR-140 expression independent of WWP2
The rsmiR-140 sequence has several potential binding sites
for transcription factors, such as NMP4 (CAAAAA), MAZ
(GAGAGA), NFAT (GGAAA) and SMAD3 (CAGA,
TTGGTGTTGG) (Figure 2A). To examine whether these
factors could be responsible for the differential regulation
of miR-140 and WWP2, their expression was silenced in
OA chondrocytes and the miR-140 and WWP2 levels were
determined (Figure 3). As both miR-140 s are similarly de-
creased in OA chondrocytes, further experiments were
carried out with miR-140-5p.
Silencing NFAT3 significantly decreased (P ≤0.01)
miR-140 expression without affecting WWP2, and silen-
cing SMAD3 significantly increased (P ≤0.05) miR-140
without significantly affecting WWP2. Silencing NFAT5
significantly decreased (P ≤0.003) miR-140 and, to athe miR-140 precursor (pre-miR-140) stem-loop located in intron 16 of
ure miRNAs. The arrows delineate the DNA sequence upstream of the
pGL3-basic vector and identified as miR-140 regulatory sequence
B) The rsmiR-140 (1.153 kb and 1.883 kb) activities were determined
units per μg of protein; the control (pGL3-basic) was assigned an
d as fold change over control. P values were assessed by the
Figure 3 Inhibition of expression (siRNAs) and phosphorylation (SIS3). Effect of silencing (siRNA) the expression of MAZ, NMP4, NFAT1-5, and
SMAD3 on A) WWP2 and B) miR-140 expression in human osteoarthritic chondrocytes (n = 7 to 10). Effect of inhibiting SMAD3 phosphorylation
following incubation of osteoarthritic chondrocytes (n = 8) without (control) or with the specific SMAD3 phosphorylation inhibitor SIS3 on the
C) WWP2 and D) miR-140 expression. Each control (random-treated cells) was assigned an arbitrary value of 1 and the effect of the treatment
evaluated as fold change over control. P values were assessed by the one-sample t-test, comparing the treated chondrocytes to the controls.
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NMP4 significantly increased WWP2 (P ≤0.05) but not
miR-140, and silencing NFAT1, NFAT2, NFAT4 or MAZ
did not significantly affect either miR-140 or WWP2
levels. To further investigate SMAD3, OA chondrocytes
were treated with the specific inhibitor of SMAD3 phos-
phorylation SIS3 (Figure 3C, D). Data showed a pattern
similar to that of the silenced SMAD3; WWP2 expres-
sion was not affected (Figure 3C) and miR-140 expres-
sion was significantly increased (P ≤0.003) (Figure 3D).
The effects of SMAD3, NFAT3 and NFAT5 were in-
vestigated in OA chondrocytes by activating SMAD3 by
TGF-β, NFAT3 by increasing calcium flux with ionomy-
cin and NFAT5 by hypertonic stress via increasing NaCl
concentration. The concentrations used and durations of
exposure resulted in an accumulation of the molecules
in the nucleus as shown by Western blot (Figure 4). As
illustrated in Figure 5A and B, ionomycin significantly
increased (P ≤0.05) miR-140 but not WWP2 expression,
while NaCl increased both WWP2 and miR-140 expres-
sion levels but significance was reached only for WWP2
(P ≤0.03). TGF-β significantly decreased (P ≤0.05) miR-
140 but had no true effect on WWP2 levels. Comple-
mentary experiments evaluating the expression of the
WWP2 variants 1 and 2 also showed no effect of iono-
mycin or TGF-β, but a significant increase with NaCl
treatment (Additional file 3: Figure S3 B). Additionalexperiments were performed to determine the expres-
sion level of a known miR-140 direct target, IGFBP5.
Data demonstrated (Figure 5C) that the increased ex-
pression of miR-140 following stimulation by ionomycin
and NaCl resulted in decreased expression of IGFBP5,
and the TGF-β-induced decrease in miR-140 led to an
increased expression of IGFBP5, indicating that a change
in miR-140 expression was reflected on its target gene.
All together, these findings confirm that NFAT3 and
SMAD3 affect miR-140 expression independently of
WWP2. It is possible that the increased expression of
miR-140 caused by NFAT5 under hypertonic conditions
results in part from increased expression of its host gene
WWP2.
Ionomycin and TGF-β regulate rsmiR-140 activity
We further examined whether the regulation by NFAT3,
NFAT5 and SMAD3 of miR-140 occurred at the level of
rsmiR-140. SW1353 cells were transfected with the
rsmiR-140 plasmid and treated with ionomycin, NaCl
and TGF-β (Figure 5D). rsmiR-140 was significantly
stimulated by ionomycin (P <0.0003), decreased by
TGF-β (P <0.01) and not affected by NaCl. To verify that
SMAD3, but not SMAD1, was involved in miR-140
regulation, the cells were treated with BMP2 (10 ng/ml);
rsmiR-140 activity was not affected by this factor (data
not shown). This result agrees with our previous finding
Figure 4 Nuclear translocation of NFAT3, NFAT5 and SMAD3 as determined by Western blotting. Human osteoarthritic chondrocytes
(n = 4) were treated with ionomycin (60 minutes), NaCl (60 minutes) and TGF-β (30 minutes) to activate and translocate NFAT3, NFAT5 and
SMAD3, respectively. Nuclear extracts from the control and treated cells were processed for Western blotting with specific antibodies. Nucleolin,
a housekeeping nuclear protein, was used as control. TGF-β, transforming growth factor β.
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http://arthritis-research.com/content/15/6/R197that BMP2, as opposed to TGF-β, does not significantly
affect miR-140 expression [5].
We next investigated whether NFAT3 and NFAT5
could act through TGF-β, as the TGF-β promoter con-
tains potential NFAT binding sites [GenBank:J04431.1].
NFAT3 and NFAT5 expression was silenced in OA chon-
drocytes and the TGF-β levels determined (Figure 5E).
Interestingly, NFAT3 did not affect TGF-β expression, but
NFAT5 significantly decreased its levels (P = 0.054).
Together, these results indicate that the TGF-β-induced
miR-140 down-regulation is the result of SMAD3 activa-
tion and that NFAT3 regulates miR-140 directly, likely at
the rsmiR-140 level. NFAT5 could indirectly contribute to
the down-regulation of miR-140 by up-regulating theFigure 5 Effect of ionomycin, NaCl, and TGF-β on miRNA and mRNA e
flux (ionomycin), hypertonic stress (NaCl) and TGF-β on A) WWP2, B) miR-1
(n = 7 to 12), and on D) the miR-140 regulatory sequence (rsmiR-140) in SW
TGF-β expression in human osteoarthritic chondrocytes (n = 5). Effect of spec
(−195 bp CAGA to TACC) binding sites on rsmiR-140 activity in SW1353 (n = 1
the effect of the treatment evaluated as fold change over control. P values we
to the controls or as underlined. miRNA, microRNA; TGF-β, transforming growexpression of TGF-β, which in turn inhibits miR-140
expression.
Identification of NFAT and SMAD3 regulatory binding
sites on rsmiR-140
rsmiR-140 has consensus binding sites for NFAT
(GGAAA at position -234 bp) and SMAD3 (CAGA at
position -209 bp and -195 bp, and TTGGTGTTGG
at -120 bp) (Figure 2A). To determine if NFAT3 and
SMAD3 directly acted through those sites, SW1353
cells were transfected with rsmiR-140 without or with
the mutated sites and treated with ionomycin and
TGF-β. Mutation of the NFAT site (Figure 5F) significantly
decreased basal (P ≤0.0001) as well as the ionomycin-xpression and rsmiR-140 activity. The effect of increasing calcium
40 and C) IGFBP5 expression in human osteoarthritic chondrocytes
1353 cells (n = 6 to 9). E) Effect of silencing NFAT3 and NFAT5 on
ific mutations of F) NFAT3 (−234 bp GGAAA to GGTAC) and G) SMAD3
0). Each control (untreated cells) was assigned an arbitrary value of 1 and
re assessed by the one-sample t-test, comparing treated chondrocytes
th factor β.
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of this site in the positive regulation of miR-140 by NFAT3.
The -195 bp CAGA mutation (Figure 5G) resulted in
a significant increase in basal (P ≤0.003) and TGF-β-
induced (P ≤0.005) expression, suggesting its involve-
ment in the negative regulation of miR-140 by TGF-β
through the inhibitory action of SMAD3. Mutating
the -120 bp TTGGTGTTGG and -209 bp CAGA sites did
not affect either basal or TGF-β-induced expression (data
not shown). It was also observed that TGF-β treatment of
the -195 bp mutated construct resulted in a slightly de-
creased expression. TGF-β has a number of roles and acts
through many intermediates in addition to SMAD3; it is
thus possible that TGF-β could act indirectly on rsmiR-
140 through other (unknown) binding sites.
NFAT3 and SMAD3 physically interact with rsmiR-140
ChIP assays were done to determine if NFAT3 and
SMAD3 physically associated with the identified sites.
OA chondrocytes were treated with ionomycin and
TGF-β and processed for ChIP assays (Figure 6). The re-
sults (Figure 6A, B, D, E) showed that treatment with
ionomycin and TGF-β significantly enriched the DNA
sequences containing the binding sites of NFAT3 and
SMAD3 (P ≤0.05, P ≤0.01, respectively). Similar experi-
ments done with primer pairs located 800 bp upstream
of the binding sites and on the unrelated negative
control gene MAP1A revealed no significant binding
(Figure 6C, F), suggesting that the increased binding
seen with treatment with TGF-β and ionomycin was
specific for rsmiR-140.
TGF-β interferes with NFAT3 translocation
As TGF-β production is significantly increased in OA
[24,25], we examined whether TGF-β could interfereFigure 6 ChIP assays of NFAT3 and SMAD3 on rsmiR-140.. Human oste
immunoprecipitation (ChIP) assay and representative gels using primers sp
and C) unrelated control gene MAP1A (amplified fragment of 211 bp); D) S
E) rsmiR-140 sequence (amplified fragment of 253 bp) and F) unrelated co
IgG, input: 1% of the starting genomic DNA lysate. Cells received no treatm
Each control (panels A and D) was assigned an arbitrary value of 1 and the
assessed by the one-sample t-test, comparing treated chondrocytes to conwith the translocation of NFAT3 and prevent its action.
As expected (Figure 7A, B), ionomycin significantly trig-
gered the translocation of NFAT3 (47%, P ≤0.001), and
TGF-β triggered that of SMAD3 (52%, P ≤0.0001) in OA
chondrocytes. Treatment with TGF-β alone had no sig-
nificant effect on NFAT3 translocation and treatment
with ionomycin alone had no effect on SMAD3 trans-
location. However, when TGF-β was added for the last
30 minutes of the 90-minute ionomycin treatment, there
was a significant decrease in the number of NFAT3-
positive nuclei (P ≤0.05) when compared to ionomycin
alone (Figure 7A). When ionomycin was added for the
last 60 minutes of the 90-minute TGF-β treatment, there
was a slight but non-significant decrease in SMAD3-
positive nuclei (Figure 7B). Similar experiments done
with human normal chondrocytes revealed the same
pattern, that is, TGF-β interfered with the ionomycin-
induced translocation of NFAT3 into the nucleus
(data not shown).
Further experiments were done to verify whether such
interference affected miR-140 expression (Figure 7C, D).
The addition of TGF-β during the ionomycin treatment
resulted in a significant decrease (P ≤0.02) in miR-140
compared to ionomycin treatment alone, while the
addition of ionomycin to the TGF-β treatment did not
significantly affect the miR-140 expression level. All to-
gether, these results indicate that the presence of TGF-β
interferes with the ionomycin-induced nuclear transloca-
tion of NFAT3 and ultimately miR-140 expression.
Discussion
Our previous study in human chondrocytes [5] and
those of others in mouse cells [6,8] identified target
genes down-regulated by miR-140 that are important in
the OA cartilage process.oarthritic chondrocytes (n = 7 to 8) in A) NFAT3 chromatin
ecific to the B) rsmiR-140 sequence (amplified fragment of 253 bp)
MAD3 ChIP assay and representative gels using primers specific to the
ntrol gene MAP1A (amplified fragment of 211 bp). IgG: pre-immune
ent (control) or were treated with B), C) ionomycin or E), F) TGF-β.
amplification evaluated as fold change over control. P values were
trols. IgG, immunoglobulin G; TGF-β, transforming growth factor β.
Figure 7 Translocation of NFAT3 and SMAD3 to the nucleus. Translocation of A) NFAT3 and B) SMAD3 in the nuclei of human osteoarthritic
chondrocytes (n = 7 to 10). For NFAT3, cells received no treatment (control) or were treated with TGF-β for 30 minutes or with ionomycin for
90 minutes without or with TGF-β added for the last 30 minutes. For SMAD3, cells received no treatment (control) or were treated with ionomycin
for 60 minutes or with TGF-β for 90 minutes without or with ionomycin added for the last 60 minutes. Representative immunocytochemistry of the
translocation of A) NFAT3 in the control, TGF-β, ionomycin, and ionomycin/TGF-β treated osteoarthritic chondrocytes for the abovementioned time
period, and B) SMAD3 in the control, ionomycin, TGF-β, and TGF-β/ionomycin-treated cells for the abovementioned time period. The percentage of
NFAT3 and SMAD3 (green stain) nuclear translocation was calculated relative to the number of total cells (nuclei stained blue with DAPI). The white
arrow-heads identify positive-nuclei. P values were assessed by the Mann–Whitney test comparing treatments to controls or as underlined. Effect of
C) TGF-β on the ionomycin-induced expression of miR-140 and of D) ionomycin on the TGF-β-induced expression of miR-140. Human osteoarthritic
chondrocytes (n = 7) were treated for 8 hours with ionomycin with or without the addition of TGF-β for the last 6 1/2 hours, or with TGF-β for 8 hours
without or with the addition of ionomycin for the last 6 1/2 hours. RNA was extracted and the expression of miR-140 was measured. C) and D) each
control (ionomycin and TGF- β, respectively) was assigned an arbitrary value of 1 and the effect of the double treatment evaluated as fold change
over control. P values were assessed by the one-sample t-test, comparing the double treated chondrocytes to the autologous control. DAPI,
4’,6-diamidino-2-phenylindole, dihydrochloride; TGF-β, transforming growth factor β.
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http://arthritis-research.com/content/15/6/R197We report, for the first time, a differential expression
between miR-140 and its host gene. We also identify a
regulatory sequence located directly upstream of the
pre-miR-140 and demonstrate the direct involvement of
NFAT3 and SMAD3 on the miR-140 regulatory se-
quence sites as well as the indirect effect of NFAT5, pos-
sibly acting through WWP2 and TGF-β. In turn, the
effects of these factors on miR-140 were translated into
the cells and impacted a known direct miR-140 target,
IGFBP5. This study also shows the importance of TGF-β
as a factor implicated in the decreased miR-140 expres-
sion in human OA chondrocytes, thus contributing to
the progression of this disease.
It was first believed that the regulation of intronic
miRNAs followed that of their host genes as they are
often co-expressed. However, recent reports showed that
some intronic miRNAs have their own promoter and
that their expression/regulation differs from that of their
host gene [26-28]. The differential expression levels of
WWP2 and miR-140 in OA chondrocytes [5,6] led us to
believe that this miRNA was controlled by intronic regu-
latory sequences in addition to the WWP2 promoter.
Other evidence of differential regulation was shown in
zebrafish [29] in which miR-140 and WWP2 were sug-
gested to play distinct roles in cartilage development, asthe separate knockdown of WWP2 and miR-140 caused
different effects.
Differential regulation between a miRNA and its host
gene may not be a rare event as we have also noted that
miR-151 expression, like that of miR-140, is decreased in
OA independently of its host gene. However, unlike
miR-140, miR-151 has not been identified in miRNA
profiling of OA cartilage [30,31], but has been associated
with carcinomas [32]. Furthermore, a search through the
literature has not revealed any family relationship be-
tween the two miRNAs; an in silico analysis of the 2 kb
sequence located upstream of the mature miR-151 did
not reveal any NFAT3 or SMAD3 consensus binding
sites, as was the case with miR-140. Although the ex-
pression levels of both miR-140 and miR-151 are de-
creased in OA, their regulation is likely the result of
different factors. Thus, the role of miR-151 in OA, direct
or indirect, is yet to be determined.
We have identified rsmiR-140 as a regulatory sequence
for miR-140 expression independently of its host gene.
This sequence is located in a region different from the
regulatory sequence identified by Yang et al. [33] and
the two sequences are likely controlled by different fac-
tors. This is in agreement with a search through the
miRStart database [34], which revealed two potential
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http://arthritis-research.com/content/15/6/R197transcription start sites (TSS) within the 50,000 bp up-
stream region of the miR-140 precursor. The first is at
position 8,070 bp upstream of the precursor and falls
within intron 10 of the WWP2 gene, upstream of the
ATG start of the WWP2-C variant as hypothesized by
Soond et al. [23] and described by Yang et al. [33]. It is
possible that this TSS is used to initiate WWP2-C tran-
scription as miR-140 was reported to be co-expressed
with WWP2-C [33]. In the Yang et al. article [33], how-
ever, there are no results showing that the expression of
WWP2-C is differentially regulated from that of miR-
140. The second TSS is located at position 976 bp up-
stream of the pre-miR-140, thus within the cloned
rsmiR-140 sequence, which we have shown to be capable
of promoting transcription independently of WWP2, un-
like the region identified by Yang et al. [33].
Another difference from the results of Yang et al. [33]
is that they found that the C-isoform (variant 2) was
abundantly expressed in chondrocytes from mouse limb
buds compared to the N- and FL-isoforms which were
absent in those cells. This is in contrast to the present
findings using human normal and OA chondrocytes in
which both the FL and N-isoforms are expressed, but
the C-isoform is very weakly or not expressed. The dif-
ference between our results and those of Yang et al. are
not surprising, as the events occurring in mouse limb
buds do not necessarily represent what is occurring in
human adult articular cartilage.Figure 8 Hypothesis on the regulation of miR-140 in human normal a
NFAT5. In normal human chondrocytes, mechano-transduction triggers ca
nucleus, where it will up-regulate miR-140. NFAT5, activated under hyperto
TGF-β are low in normal cartilage, the end result will be a positive regulatio
TGF-β and data showed that the expression levels of NFAT5 are decreased
(data not shown). Thus, TGF-β will increase SMAD3 phosphorylation and di
by interfering with the translocation of NFAT3. Therefore, in osteoarthritic c
SMAD3 negative regulation of miR-140 levels would prevail over the NFAT
miRNA in these cells. miRNA, microRNA; TGF-β, transforming growth factorMutagenesis has identified functional NFAT3 (GGAAA)
and SMAD3 (CAGA) binding sites. Of interest is the op-
posite direct regulation of miR-140 by NFAT3 (activator)
and SMAD3 (inhibitor). Such competition/cooperation
between these two factors has previously been reported
in different systems, an example being the human c-
Myc transcription, activated by NFATs and repressed
by TGF-β [35].
This study also identifies NFAT5 as an indirect regula-
tor of miR-140 expression. The differential activity of
NFAT5 and NFAT3, although both belong to the same
family of transcription factors, is not surprising as they
are activated by different factors, have different binding
partners and control the transcription of different genes
[36-40]. The up-regulation of WWP2/miR-140 under
hypertonic conditions could occur via the transcription
factor Sox9, as WWP2 and miR-140 were reported to be
co-expressed and activated by Sox9 [33] and Sox9 is up-
regulated by osmotic stress in human chondrocytes [41].
NFAT5 is also active under isotonic conditions [42]. It
was suggested to participate in carcinoma invasion [43]
and was found to be a critical regulator of proliferation/
survival of synoviocytes in rheumatoid arthritis [44]. Here,
we show that, in an isotonic environment, NFAT5 could
indirectly down-regulate miR-140 through the stimulation
of TGF-β and subsequent activation of SMAD3.
The importance of TGF-β in OA has been recognized
and reviewed [45,46] and is reported to have a dualisticnd osteoarthritic chondrocytes by TGF-β, SMAD3, NFAT3 and
lcium signaling and the subsequent translocation of NFAT3 to the
nic stress, up-regulates WWP2 and miR-140 expression. As the levels of
n. In osteoarthritic cartilage, there is a marked increased expression of
compared to normal human cartilage but those of NFAT3 are stable
rectly inhibit miR-140. TGF-β will also indirectly down-regulate miR-140
hondrocytes, the NFAT5 contribution will be lower and the TGF-β/
3 and NFAT5 positive regulation and account for the decrease in this
β.
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http://arthritis-research.com/content/15/6/R197role in articular tissue. It protects against cartilage damage
by inducing expression of extracellular matrix production,
but it also induces osteophyte formation [47,48] and
MMP-13 expression [24,49]. This study reveals another
pathway by which TGF-β affects OA chondrocytes: as a
down-regulator of miR-140 expression, not only by activat-
ing SMAD3 but also by interfering with the translocation
of NFAT3. Although the exact mechanism of this interfer-
ence in chondrocytes remains to be determined, it could
occur through a mechanism similar to that described in T-
cells in which TGF-β inhibits the phosphorylation of the
Tec kinase acting upstream of NFAT activation, thus
blocking NFAT translocation into the nuclei [50]. Besides
the direct role of TGF-β on miR-140 regulation, it is also
known to regulate targets of miR-140, such as IGFBP-5 [5]
and SMAD3 [51]. Indeed, our group reported that TGF-β
increased IGFBP-5 expression in human OA chondrocytes
and Baugé et al. [51] found that treating OA chondrocytes
for a short period of time up-regulated SMAD3 expression,
but a longer period resulted in a decreased expression.
Thus, TGF-β affects many genes and its regulation through
miRNAs is part of this complex network.
Data from this study support the hypothesis that miR-
140 expression could be regulated at different levels
under normal and OA conditions (Figure 8). Although
the thrust of this study was to look at the regulation of
miR-140 during a pathological condition, that is, OA, it
would also be of interest to evaluate the effects of factors
on normal chondrocytes. However, being beyond the
scope of the present study, this topic should be explored
in another work. Nonetheless, a hypothesis could be as
follows. In normal cells, mechano-transduction triggers
calcium signaling [52,53] and translocation of NFAT3 to
the nucleus, where it will up-regulate miR-140. NFAT5,
activated under hypertonic stress, up-regulates WWP2
and miR-140 expression. As the levels of TGF-β are low
in normal cartilage, the end result will be a positive regula-
tion. In OA chondrocytes, the increased expression of
TGF-β would activate SMAD3 phosphorylation, thus dir-
ectly inhibiting miR-140 as well as indirectly down-
regulating miR-140 by interfering with the translocation
of NFAT3. Therefore, in OA chondrocytes, as the NFAT5
expression is decreased compared to that in normal chon-
drocytes (data not shown), the NFAT5 contribution in OA
will be lower. However, as TGF-β is increased in OA but
the expression of NFAT3 is similar in normal and OA
(data not shown), the negative regulation of miR-140
levels by TGF-β/SMAD3 would prevail over the positive
regulation by NFAT3 and would account for the de-
creased miRNA in these cells.
Conclusions
In summary, this study is the first to show the important
direct roles of NFAT3 and SMAD3 and the indirect roleof NFAT5 in miR-140 expression. Moreover, we highlight
a new role for TGF-β in OA chondrocytes as a down-
regulator of miR-140 expression, resulting in increased ex-
pression of miR-140 target genes, thus contributing to this
disease process. These data could open up novel avenues
in OA therapeutic strategy.
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